[go: up one dir, main page]

NO20084660L - Farmasoytiske preparater: salter av 8-[{l-(3,5-bis-(trifluormetyl)fenyl)etoksy}metyl] -8-fenyl-1,7-diaza-spiro [4 5]dekan-2-on og behandlingsfremgangsmater ved anvendelse av disse - Google Patents

Farmasoytiske preparater: salter av 8-[{l-(3,5-bis-(trifluormetyl)fenyl)etoksy}metyl] -8-fenyl-1,7-diaza-spiro [4 5]dekan-2-on og behandlingsfremgangsmater ved anvendelse av disse

Info

Publication number
NO20084660L
NO20084660L NO20084660A NO20084660A NO20084660L NO 20084660 L NO20084660 L NO 20084660L NO 20084660 A NO20084660 A NO 20084660A NO 20084660 A NO20084660 A NO 20084660A NO 20084660 L NO20084660 L NO 20084660L
Authority
NO
Norway
Prior art keywords
phenyl
decan
trifluoromethyl
ethoxy
bis
Prior art date
Application number
NO20084660A
Other languages
English (en)
Other versions
NO342810B1 (no
Inventor
Zhihui Qiu
Larisa Reyderman
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38441502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20084660(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20084660L publication Critical patent/NO20084660L/no
Publication of NO342810B1 publication Critical patent/NO342810B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Farmasøytiske preparater som inneholder salter av (5S,8S)-8-[ { (1R)-1-(3,5-bis-trifluormetyl)fenyl]-etoksy}metyl]-8-fenyl-l,7-diazaspiro[4.5]dekan-2-on, representert ved formel I, beskrives. Videre beskrives fremgangsmåter for behandling ved benyttelse av slike doseringsformer.
NO20084660A 2006-04-05 2008-11-04 Farmasøytiske preparater: salter av 8-[{l-(3,5-bis-(trifluormetyl)fenyl)etoksy}metyl]-8-fenyl-1,7-diaza-spiro[4.5]dekan-2-on og anvendelse av disse NO342810B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78951406P 2006-04-05 2006-04-05
PCT/US2007/008345 WO2007114921A2 (en) 2006-04-05 2007-04-04 Pharmaceutical formulations: salts of 8-[{1-(3,5-bis (trifluoromethy1)pheny1)-e thoxy}-methy1]-8-pheny1-1,7-diaza-spiro[4.5] decan-2-one and treatment methods using the same

Publications (2)

Publication Number Publication Date
NO20084660L true NO20084660L (no) 2008-11-04
NO342810B1 NO342810B1 (no) 2018-08-13

Family

ID=38441502

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084660A NO342810B1 (no) 2006-04-05 2008-11-04 Farmasøytiske preparater: salter av 8-[{l-(3,5-bis-(trifluormetyl)fenyl)etoksy}metyl]-8-fenyl-1,7-diaza-spiro[4.5]dekan-2-on og anvendelse av disse

Country Status (19)

Country Link
US (4) US7563801B2 (no)
EP (2) EP2004148B1 (no)
JP (4) JP5155998B2 (no)
KR (1) KR20080108319A (no)
CN (2) CN101460151B (no)
AR (1) AR060303A1 (no)
AU (1) AU2007233389C1 (no)
BR (1) BRPI0710577A2 (no)
CA (2) CA2648640C (no)
CL (1) CL2007000945A1 (no)
ES (1) ES2553805T3 (no)
MX (1) MX2008012936A (no)
NO (1) NO342810B1 (no)
NZ (1) NZ571693A (no)
PE (2) PE20080054A1 (no)
SG (1) SG10201500028RA (no)
TW (1) TWI332836B (no)
WO (1) WO2007114921A2 (no)
ZA (1) ZA200808465B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
JP5352446B2 (ja) * 2006-04-05 2013-11-27 オプコ ヘルス， インコーポレイテッド ８−［｛１−（３，５−ビス−（トリフルオロメチル）フェニル）−エトキシ｝−メチル］−８−フェニル−１，７−ジアザ−スピロ［４．５］デカン−２−オンの塩酸塩およびその調製プロセス
AU2007233389C1 (en) * 2006-04-05 2013-07-25 Opko Health, Inc. Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
AR066191A1 (es) 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
PE20081891A1 (es) * 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
HUE026148T2 (en) 2008-09-05 2016-05-30 Opko Health Inc 8 - ({1- [3,5-bis (trifluoromethyl) phenyl] ethoxy} methyl) -8-phenyl-1,7-diaza-spiro [4,5] decane-on-compounds intermediates
WO2010077669A2 (en) * 2008-12-08 2010-07-08 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
RU2017145628A (ru) 2009-08-14 2019-02-19 ОПКО Хельс, Инк. Композиции антагонистов нейрокинина-1 для внутривенного введения
EP3002005A1 (en) * 2014-09-30 2016-04-06 Molkerei Meggle Wasserburg GmbH & Co. Kg Direct compression excipient based on lactose, cellulose and starch
CN104473887A (zh) * 2014-11-12 2015-04-01 广东东阳光药业有限公司 一种提高利伐沙班片溶出曲线重现性的方法
CN106866669A (zh) * 2017-04-19 2017-06-20 成都百特万合医药科技有限公司 一种合成罗拉吡坦中间体的方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US431003A (en) * 1890-06-24 Store-service apparatus
GB1605190A (en) * 1968-08-23 1983-03-23 Phillips Petroleum Co Armour plate
US4013613A (en) * 1971-10-01 1977-03-22 General Electric Company Reinforced intercrystalline thermoplastic polyester compositions
US4079161A (en) * 1974-07-12 1978-03-14 Phillips Petroleum Company Transparent oriented polyolefin laminated armor structure
FR2678971B1 (fr) * 1991-07-08 1998-04-10 Andre Giraud Elements de structure composite transparents et leurs procedes de fabrication.
US5830548A (en) * 1992-08-11 1998-11-03 E. Khashoggi Industries, Llc Articles of manufacture and methods for manufacturing laminate structures including inorganically filled sheets
US5665450A (en) * 1992-08-21 1997-09-09 The Curators Of The University Of Missouri Optically transparent composite material and process for preparing same
DE69327541T2 (de) 1992-10-28 2000-08-10 Merck Sharp & Dohme Ltd., Hoddesdon 4-arylmethyloxymethyl piperidine als tachykinin antagonisten
CA2150951A1 (en) 1992-12-14 1994-06-23 Angus Murray Macleod 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists
ATE170174T1 (de) 1994-01-13 1998-09-15 Merck Sharp & Dohme Gem-bissubstituierte azazyclische tachykinin- antagonisten
US5733659A (en) * 1995-02-27 1998-03-31 Mitsubishi Engineering-Plastics Corporation Transparent rigid resin molded product and process for producing the same
DK0812195T3 (da) * 1995-02-28 2003-03-03 Aventis Pharma Inc Farmaceutisk sammensætning til piperidinoalkanolforbindelser
WO1997007804A1 (en) 1995-08-28 1997-03-06 Schering Corporation Combination therapy for advanced cancer comprising temozolomide and cisplatin
US5759658A (en) * 1996-04-26 1998-06-02 Tables International Corporation Composite panels, articles incorporating same and method
US5939098A (en) 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US6630231B2 (en) * 1999-02-05 2003-10-07 3M Innovative Properties Company Composite articles reinforced with highly oriented microfibers
HUP0200805A3 (en) * 1999-03-30 2004-07-28 Schering Corp Improved cancer treatment with temozolomide
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
DE10053151A1 (de) * 2000-10-26 2002-05-08 Bayer Ag Zusammensetzung enthaltend thermoplastische Kunststoffe
ES2291538T3 (es) 2001-11-13 2008-03-01 Schering Corporation Antagonistas de nk1.
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
US6818306B2 (en) * 2002-09-27 2004-11-16 The Boeing Company Optically clear structural laminate
AU2004278158B2 (en) * 2003-10-03 2009-08-13 Pfizer Inc. Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation
US6889938B1 (en) * 2003-10-21 2005-05-10 The Boeing Company Structural cockpit window and method of making same
WO2005063243A1 (en) * 2003-12-22 2005-07-14 Schering Corporation Pharmaceutical compositions
SG187416A1 (en) 2004-07-01 2013-02-28 Opko Health Inc Piperidine derivatives as nk1 antagonists
JP2008519584A (ja) 2004-11-09 2008-06-12 シェーリング コーポレイション 患者のｍｇｍｔレベルに基づいて癌を処置するための、テモゾロミドの改良された投薬養生法
JP5352446B2 (ja) 2006-04-05 2013-11-27 オプコ ヘルス， インコーポレイテッド ８−［｛１−（３，５−ビス−（トリフルオロメチル）フェニル）−エトキシ｝−メチル］−８−フェニル−１，７−ジアザ−スピロ［４．５］デカン−２−オンの塩酸塩およびその調製プロセス
AU2007233389C1 (en) * 2006-04-05 2013-07-25 Opko Health, Inc. Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
PE20081891A1 (es) 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
AR066191A1 (es) 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
HUE026148T2 (en) 2008-09-05 2016-05-30 Opko Health Inc 8 - ({1- [3,5-bis (trifluoromethyl) phenyl] ethoxy} methyl) -8-phenyl-1,7-diaza-spiro [4,5] decane-on-compounds intermediates
RU2017145628A (ru) 2009-08-14 2019-02-19 ОПКО Хельс, Инк. Композиции антагонистов нейрокинина-1 для внутривенного введения

Also Published As

Publication number Publication date
CN103751186A (zh) 2014-04-30
NZ571693A (en) 2011-12-22
CN101460151A (zh) 2009-06-17
CA2861281A1 (en) 2007-10-11
ES2553805T3 (es) 2015-12-11
CA2648640A1 (en) 2007-10-11
SG10201500028RA (en) 2015-02-27
HK1133387A1 (en) 2010-03-26
AU2007233389C1 (en) 2013-07-25
US8404702B2 (en) 2013-03-26
CN101460151B (zh) 2013-11-20
US9345692B2 (en) 2016-05-24
PE20120254A1 (es) 2012-03-26
EP2997964A1 (en) 2016-03-23
CN103751186B (zh) 2016-08-24
TW200808312A (en) 2008-02-16
PE20080054A1 (es) 2008-02-25
AR060303A1 (es) 2008-06-04
US7563801B2 (en) 2009-07-21
JP2013049720A (ja) 2013-03-14
WO2007114921A2 (en) 2007-10-11
EP2004148B1 (en) 2015-07-15
JP6035305B2 (ja) 2016-11-30
JP5640065B2 (ja) 2014-12-10
JP5415587B2 (ja) 2014-02-12
CL2007000945A1 (es) 2008-01-25
WO2007114921A3 (en) 2008-03-27
EP2004148A2 (en) 2008-12-24
JP2009532473A (ja) 2009-09-10
AU2007233389B2 (en) 2013-02-28
JP2012167125A (ja) 2012-09-06
KR20080108319A (ko) 2008-12-12
CA2648640C (en) 2016-02-16
BRPI0710577A2 (pt) 2011-08-16
US7981905B2 (en) 2011-07-19
JP2015071603A (ja) 2015-04-16
MX2008012936A (es) 2008-10-15
NO342810B1 (no) 2018-08-13
US20070275051A1 (en) 2007-11-29
US20120015921A1 (en) 2012-01-19
TWI332836B (en) 2010-11-11
ZA200808465B (en) 2011-03-30
AU2007233389A1 (en) 2007-10-11
JP5155998B2 (ja) 2013-03-06
US20100137348A1 (en) 2010-06-03
US20140088128A1 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
NO20084660L (no) Farmasoytiske preparater: salter av 8-[{l-(3,5-bis-(trifluormetyl)fenyl)etoksy}metyl] -8-fenyl-1,7-diaza-spiro [4 5]dekan-2-on og behandlingsfremgangsmater ved anvendelse av disse
MX2009010210A (es) Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-d iaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas.
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
EA201001013A1 (ru) Бис(сульфониламино)производные для применения в терапии
NO20070576L (no) Nye hydantionderivater for behandling av obstruktive luftveissykdommer.
NO20061506L (no) Heterocykliske inhibitorer av MEK og fremgangsmater for anvendelse derav
UA115131C2 (uk) Сполуки боронатного ефіру і його фармацевтичні рецептури
WO2007008257A3 (en) Method and apparatus for delivering epinephrine
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
MY144655A (en) Pyrimidine urea derivatives as kinase inhibitors
GEP20125469B (en) Inhibitors of akt activity
NO20064201L (no) Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling
NO20091889L (no) Inhibitorer av spiroketon acetyl-CoA karboksylase
WO2008074824A3 (en) Isoquinolinecarboxamides as inhibitors of stearoyl-coa desaturase (scd)
CY1108794T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
DK2368887T3 (da) 1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer
CY1109962T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας
NO20065904L (no) Terapeutiske forbindelser
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
GB0400895D0 (en) Chemical compounds
NO20070570L (no) Forbindelser.
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
EA201001858A1 (ru) Гетероциклические производные мочевины для лечения бактериальных инфекций

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees